A single intranasal dose of 6.8 mg neuropeptide Y reduced depression scores significantly at 24 hours (d=0.67) vs placebo in 30 MDD patients already on antidepressants.
MADRS -10.3 at 24hSingle intranasal NPY dose reduced depression scores twice as much as placebo at 24 hours
What the researchers found
Single-dose intranasal NPY (6.8 mg) reduced MADRS by 10.3 points at 24h vs 5.6 for placebo (P=0.04, d=0.67) in MDD patients; effect not significant at 48h.
Why it matters
One-third of depression patients don't respond to existing medications. NPY represents a completely novel mechanism — replacing a brain peptide that's depleted in depression.
The numbers in context
6.8 mg single dose; MADRS -10.3 vs -5.6 at 24h (p=0.04, d=0.67); -7.1 vs -3.5 at 5h (p=0.05, d=0.61); 48h NS
How the study worked
Double-blind RCT: 30 MDD patients on stable antidepressants; 12 received 6.8 mg intranasal NPY, 18 placebo; MADRS assessed at baseline, +1h, +5h, +24h, +48h.
Who was studied
30 patients with major depressive disorder on stable antidepressants (12 NPY, 18 placebo)
What this study cannot tell us
Very small sample (n=30, unequal groups 12 vs 18); primary endpoint at 48h not met; single dose — duration of effect unknown with repeated dosing; add-on to antidepressants only.
How to read the evidence
Moderate — first-in-kind RCT with significant secondary endpoint but missed primary endpoint; small sample size.
When this study was published
Published in 2020; intranasal peptide delivery for neuropsychiatric disorders is an emerging field.
The bigger picture
Like ketamine showed rapid antidepressant effects via a novel mechanism, intranasal NPY could represent another fast-acting approach. The neuropeptide replacement concept is compelling for neuropsychiatric disorders.
Questions still open
- Would repeated daily intranasal NPY produce sustained antidepressant effects?
- What dose provides the best balance of efficacy and duration?
- Could NPY work as monotherapy, or only as add-on?
Common questions
What is neuropeptide Y?
How does a nasal spray reach the brain?
Read the original research
A Randomized Controlled Trial of Intranasal Neuropeptide Y in Patients With Major Depressive Disorder.
The international journal of neuropsychopharmacology, 23(12), 783-790
Citation
Mathé, Aleksander A; Michaneck, Miranda; Berg, Elisabeth; Charney, Dennis S; Murrough, James W. (2020). A Randomized Controlled Trial of Intranasal Neuropeptide Y in Patients With Major Depressive Disorder.. The international journal of neuropsychopharmacology, 23(12), 783-790. https://doi.org/10.1093/ijnp/pyaa054